The multidisciplinary management of oligometastatic prostate cancer: a case report and review of literatures

doi:10.3877/cma.j.issn.1674-3253.2019.06.004

Abstract

Abstract:

Objective

To discussion the application of multidisciplinary comprehensive diagnosis and treatment of oligometastatic prostate cancer.

Methods

The clinical data of an oligometastatic prostate cancer patient treated with multidisciplinary comprehensive mode was analyzed retrospectively, and related literatures were reviewed.

Results

PSA of the patient was 60 μg/L. The pelvic MRI considered to be prostate cancer with bilateral seminal vesicle and left ureteral orifice invasion, diagnosis was confirmed by prostate biopsy and the Gleason score was 4+5, ECT scan found four bone metastases. The patient had been treated with androgen deprivation therapy since May 2016. He had undergone sequential neoadjuvant chemotherapy, cytoreductive radical prostatectomy, stereotactic radiotherapy, abiraterone + prednisone and Docetaxel chemotherapy. After follow-up until December 2018, the patient had no significant pain and discomfort, but the PSA increased.

Conclusion

Multidisciplinary treatment can prolong survival and improve quality of life in patients with oligometastatic prostate cancer.

Key words: Oligometastasis, Prostate cancer, Multidisciplinary, Synthetic therapy

Jinyou Wang, Dongdong Xie, Liangkuan Bi, Yi Wang, Dexin Yu. The multidisciplinary management of oligometastatic prostate cancer: a case report and review of literatures[J]. Chinese Journal of Endourology(Electronic Edition), 2019, 13(06): 374-377.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2019.06.004

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2019/V13/I06/374

Figures/Tables 2

References 15

[1]	Siddique O, Yoo ER, Perumpail RB, et al. The importance of a multidisciplinary approach to hepatocellular carcinoma[J]. J Multidiscip Healthc. 2017, 10: 95-100.
[2]	Tosoian JJ, Gorin MA, Ross AE, et al. Oligometastatic prostate cancer definitions, clinicail outcomes, and treatment considerations[J]. Nat Rev Urol, 2017, 14(1): 15-25.
[3]	Gupta A, Pugh TJ, Lam E, et al. The role of primary tumor treatment and metastasis-directed therapy in oligometastatic prostate cancer[J]. Oncology (Williston Park), 2019, 33(5): 187-191.
[4]	Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study[J]. Eur Urol, 2014, 65(6): 1058-1066.
[5]	Rusthoven CG, Jones BL, Flaig TW, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer[J]. J Clin Oncol, 2016, 34(24): 2835-2842.
[6]	Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study[J]. J Urol, 2015, 193(3): 832-838.
[7]	Vale Cl, Burdeet S, Rydzewska, et al. Addition of docetaxel OR bisphosphonates to standard of care in men with localized OR metastatic, hormone-sensitive prostate cancer a systematic review and meta-analyses of aggregate date[J]. Lancet Oncol, 2016, 17(2): 243-256.
[8]	Chi KN, Chowdhury S, Radziszewski P, et al. TITAN: a randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)[J]. Ann Oncol, 2016, 27(Suppl 6): vi243-265.
[9]	McClintock TR, von Landenberg N, Cole AP, et al. Neoadjuvant androgen deprivation therapy prior to radical prostatectomy: recent trends in utilization and association with postoperative surgical margin status[J]. Ann Surg Oncol, 2019, 26(1): 297-305.
[10]	Ost P, Bossi A, Decaestecker K, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature[J].2015, 67(5): 852-863.
[11]	Kim J, Park JS, Ham WS. The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer[J]. Investig Clin Urol, 2017, 58(5): 307-316.
[12]	潘家强，覃展偶. 去势抵抗性前列腺癌的临床治疗进展与处理策略[J/CD]. 中华腔镜泌尿外科杂志（电子版）, 2018, 12(1): 67-70.
[13]	de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer[J]. N EngL J Med, 2011, 364(21): 1995-2005.
[14]	Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer[J]. Eur Urol, 2017, 71(4): 630-642.
[15]	周祥福. 2018版欧洲泌尿外科前列腺癌指南要点解读[J/CD]. 中华腔镜泌尿外科杂志（电子版）, 2018, 12(5): 289-294.

Please choose a citation manager

Content to export